Takeda seals $1.2 billion oncology deal with Innovent Biologics
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
MRI is particularly valuable in pediatric care due to its non-invasive nature
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
The center will offer training to super-specialist doctors and healthcare professionals in various fields
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
The company introduced the ExcelSign E12 and E17 modular patient monitors, the Relife 1000 biphasic defibrillator, and a new OT charting software
This inspection was conducted following the warning letter issued by the USFDA
Sun Pharma to set up Rs. 3,000 crore greenfield formulations facility in MP
Subscribe To Our Newsletter & Stay Updated